Analyst Summary:
TScan Therapeutics, a clinical-stage biopharmaceutical company, has reported financial results for Q4 2022 and the full year-ended December 31, 2022. The company has $120 million in cash on hand, which it plans to use for upcoming milestones. TScan has filed three INDS for its solid tumor program and plans to file four more throughout the year. The company's lead TCR-T therapy candidates, TSC-100 and TSC-101, are in clinical development for the treatment of patients with hematologic malignancies. TScan also anticipates a broader range of multiplexed TCR-T therapies for patients. The company believes existing cash will be sufficient to fund its operational expenses and capital expenditure requirements into the second quarter of 2024. The company aims to provide customized TCR-T therapy to treat patients with a wide variety of solid tumor malignancies. There are many anticipated upcoming milestones that the company expects, based on its financial goals and strategy, and it aims to attain these milestones in the next few years through its products. Additionally, TScan recently won the Best Mid-Sized Biotechnology Company in the Top Places to Work for 2022 by The Boston Globe.